Ignite Creation Date:
2024-05-06 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 1:54 PM
Study NCT ID:
NCT04714593
Status:
UNKNOWN
Last Update Posted:
2021-01-22
First Post:
2021-01-07
Brief Title:
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
Sponsor:
Shanxi Province Cancer Hospital
Organization:
Shanxi Province Cancer Hospital
Study Overview
Official Title:
A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation the safetytolerability preliminary efficacyand PKPD of CD19-CD22 CAR-T cells for the treatment of acute B lymphocytic leukemia
Detailed Description:
A non randomized study plans to enrollment 24 subjects of acute B lymphocytic leukemia The subjects will divide into low medium and high dose groupsto evaluate the safety and tolerability of CD19-CD22 CAR - T cellsto evaluate the preliminary efficacy and observe PKPD parameters of CD19-CD22 CAR -T cells immunotherapy in patients with relapsed or refractory acute B lymphocytic leukemia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None